Tag Archives: Aduhelm

High-profile Biogen ads hype early Alzheimer’s detection as hospitals reject Aduhelm prescriptions

How do you sell an Alzheimer’s treatment mired in controversy over its disputed benefits? Biogen is turning to “Jim and Jane” for help.  That’s the couple grappling with the memory-robbing disease that Biogen and Japanese partner Eisai have placed at the center of their new marketing campaign, “It’s Time We Know.” The campaign is designed… Read More »

Aduhelm and Alzheimer’s Disease: A Potential Medicare Budget-Buster Puts A Blazing Light on Health Care Costs and Innovation

The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue). In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s… Read More »